A Mab — A Case Study In Bioprocess Development

A-Mab Case Study

The is a seminal 2009 document developed by the CMC-Biotech Working Group —a consortium including Amgen, Genentech, and Pfizer—to demonstrate how Quality by Design (QbD) principles can be applied to monoclonal antibody (mAb) bioprocessing . It serves as a practical roadmap for implementing International Council for Harmonisation (ICH) guidelines Q8(R2) , Q9 , and Q10 in a biotechnology environment. Core Framework of the A-Mab Study

| Metric | Target | Achieved | Result | |--------|--------|----------|--------| | Overall yield | >70% | 73% | Success | | Final titer | 5 g/L | 5.2 g/L | Success | | Aggregates | <1% | 0.6% | Success | | HCP | <100 ppm | 18 ppm | Success | | Potency (relative to reference) | 80-125% | 105% | Success | | Cost of goods (COGs) per gram | <$100 | $78 | Target beat | | Timeline (clone to Phase I) | 18 months | 16 months | Ahead of plan | A Mab A Case Study In Bioprocess Development

Part 7: Regulatory and Economic Outcomes

Risk Management Integration

: It demonstrates how to use systematic risk assessments (like FMEA) to justify process parameters and ranges. A-Mab Case Study The is a seminal 2009

Identification of CQAs

: Determining Critical Quality Attributes (CQAs) —such as glycosylation, aggregation, and host cell protein (HCP) levels—that must be controlled to ensure drug performance. Chemically defined media vs hydrolysate-containing

• Chemically defined media vs hydrolysate-containing; advantages for consistency.
• Fed-batch vs perfusion vs continuous manufacturing: selection criteria (target titer, cell culture longevity, facility fit).
• Feed scheduling: bolus vs continuous; real-time control strategies using DO, pH, viable cell density (VCD), metabolites (glucose, lactate, ammonia).
• Optimization parameters: C/N ratio, amino acid supplementation (e.g., asparagine, glutamine), lipid precursors, trace elements.

• Harvest: Replaced standard depth filtration with Reactive Oxygen Species (ROS) resistant flocculation using a low-dose cationic polymer. This agglomerated cells and colloids, enabling direct depth filtration at 120 L/m².
• Capture: Switched from standard rProtein A to a high-capacity, alkali-stable resin. Loaded at 10-minute residence time instead of 6 minutes to prevent mass transfer limitations. Used a salt-bath wash (0.5M Arginine) to remove HCPs without stripping the product.